Trial Profile
A Dose-finding Trial of OPC-34712 in Patients With Schizophrenia.
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 07 Dec 2021
Price :
$35
*
At a glance
- Drugs Brexpiprazole (Primary)
- Indications Schizophrenia
- Focus Therapeutic Use
- Sponsors Otsuka Pharmaceutical
- 18 May 2018 Primary endpoint of change in positive and negative syndrome scale (PANSS) total score from baseline to week 6 has not been met for brexpiprazole 1 and 4 mg versus placebo, according to results published in the Psychiatry and Clinical Neurosciences.
- 18 May 2018 Primary endpoint of change in positive and negative syndrome scale (PANSS) total score from baseline to week 6 has been met for brexpiprazole 2 mg versus placebo, according to results published in the Psychiatry and Clinical Neurosciences.
- 18 May 2018 Results published in the Psychiatry and Clinical Neurosciences